Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis - Takeaways - MDSpire

Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis

  • By

  • U Bhalraam

  • Rathna B Veerni

  • Sophie Paddock

  • James Meng

  • Massimo Piepoli

  • Teresa López-Fernández

  • Vasiliki Tsampasian

  • Vassilios S Vassiliou

  • March 6, 2025

  • 0 min

Share

  • 1

    SGLT2 inhibitors significantly reduce heart failure hospitalizations by 51% and new heart failure diagnoses by 71% in cancer patients.

  • 2

    The systematic review included 13 studies with 88,273 cancer patients, highlighting the cardiovascular benefits of SGLT2 inhibitors.

  • 3

    Breast cancer patients receiving anthracycline chemotherapy showed a 99% reduction in heart failure hospitalization risk with SGLT2 inhibitors.

  • 4

    SGLT2 inhibitors may protect heart health during and after cancer treatment, particularly in patients undergoing cardiotoxic chemotherapy.

  • 5

    Further prospective trials are needed to explore the integration of SGLT2 inhibitors into cancer patient management for improved outcomes.

Original Source(s)

Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis

  • by U Bhalraam, Rathna B Veerni, Sophie Paddock, James Meng, Massimo Piepoli, Teresa López-Fernández, Vasiliki Tsampasian, Vassilios S Vassiliou

  • March 6, 2025

Related Content

Pulmonary vein stenosis after pediatric heart transplantation: incidence and risk factors

A patient with triple-negative breast cancer developed acute myocardial infarction after docetaxel chemotherapy: case report and literature review

Corvad as a bridge to LVAD implantation in end-stage heart disease complicated by cardiogenic shock: a three-case series